Hyperion is an all-in-one finance app that integrates essential financial services for small businesses through a mobile application. Hyperion’s customers can validate a business in minutes, having access to cash management, B2B payments, financial reports, and a business network they can tap into.
Kiwi is an app that provides access to affordable capital, helps build credit, and improves financial literacy. The company was founded in 2020 and is based in San Juan, Puerto Rico.
Seven Seas Water Corporation specializes in outsourced water and wastewater treatment services for a diverse range of clients including governmental, municipal, industrial, property developers, and hospitality sectors in the United States and internationally. Founded in 1996 and headquartered in Tampa, Florida, the company provides a comprehensive suite of solutions, including desalination, advanced water treatment, and wastewater management, typically through a build-own-operate model. This approach allows Seven Seas Water to cover capital costs and manage all aspects of facility operation, ensuring clients receive a reliable water supply at a fixed rate. The company also maintains a fleet of mobile reverse osmosis units for rapid deployment in emergency situations. With a strong management team boasting over 350 years of combined experience, Seven Seas Water has established successful public-private partnerships in the Caribbean and continues to expand its presence across the Americas.
AquaVenture Holdings is a water purification company that specializes in the service industry. Through its Quench and Seven Seas Water businesses, AVH provides water solutions, utilizing state-of-the-art purification and desalination technologies. It was founded in 2006 and headquartered in Tampa, Florida.
Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.